`
`https://www.sec.gov/Archives/edgar/data/316253/000093041316007567/c85521_8k.htm
`
`8K 1 c85521_8k.htm
`
`UNITED STATES
`SECURITIES AND EXCHANGE COMMISSION
`WASHINGTON, DC 20549
`
`FORM 8K
`
`CURRENT REPORT
`PURSUANT TO SECTION 13 OR 15(D) OF THE
`SECURITIES EXCHANGE ACT OF 1934
`
`
`Date of report (Date of earliest event reported): July 1, 2016
`
`
`Enzo Biochem, Inc.
`(Exact Name of Registrant as Specified in Its Charter)
`
`New York
`(State or Other Jurisdiction of Incorporation)
`
`
`
`
`
`
`
`
`(212) 5830100
`(Registrant’s Telephone Number, Including Area Code)
`
`(Former Name or Former Address, if Changed Since Last Report)
`
`
`00109974
`(Commission File Number)
`
`527 Madison Avenue
`New York, New York
`(Address of Principal Executive Offices)
`
`
`
`132866202
`(IRS Employer Identification No.)
`
`
`10022
`(Zip Code)
`
`
`
`Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant
`under any of the following provisions (see General Instruction A.2. below):
`
` Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
`
`
`Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
`
`
`
`Precommencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
`
`
`
`Precommencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))
`
`
`
`
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041316007567/c85521_8k.htm
`
`1/3
`
`Enzo Exhibit 2130
`BD v. Enzo
`Case IPR2017-00181
`
`Exhibit 2130 Page 1
`
`
`
`1/10/2017
`
`
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041316007567/c85521_8k.htm
`
`
`Item 8.01. Other Events.
`
` Enzo Biochem, Inc. (NYSE:ENZ) announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a
`settlement with Illumina, Inc. (Nasdaq: ILMN) that included a payment of $21 million to Enzo in an action brought in Delaware
`Federal District Court by Enzo alleging infringement of its U.S. Patent No. 7,064,197, entitled System, Array and NonPorous Solid
`Support Comprising Fixed or Immobilized Nucleic Acids.
`
`
` This settlement resolving the dispute between Enzo Life Sciences and Illumina impacts only one of 11 cases originally
`brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various
`companies, five of which are now resolved and six of which remain pending.
`
`Item 9.01. Financial Statements and Exhibits.
`
`(d) Exhibits.
`
`Exhibit No. Description
`
`
`99.1
`Press Release of Enzo Biochem, Inc., dated July 7, 2016.
`
`
`
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041316007567/c85521_8k.htm
`
`2/3
`
`Exhibit 2130 Page 2
`
`
`
`1/10/2017
`
`
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041316007567/c85521_8k.htm
`
`
`
`
`
`
`
`
`Date: July 7. 2016
`
`
`
`
`
`SIGNATURES
`
`Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report
`to be signed on its behalf by the undersigned hereunto duly authorized.
`
`
`ENZO BIOCHEM, INC.
`
`By: /s/ Barry W. Weiner
`
`Barry W. Weiner
`
`President
`
`
`
`
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041316007567/c85521_8k.htm
`
`3/3
`
`Exhibit 2130 Page 3
`
`